this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->



ZY7 is found in 1 entry

ZY7 as free ligands, exist in 1 entry. Example includes: 2WNJ

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

FormulaC19 H20 N2 O2
Molecular Weight308.37 g/mol
Isomeric SMILESCOc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1

Chemical Details

Formal Charge0
Atom Count43
Chiral Atom Count0
Chiral Atomsn/a
Bond Count45
Aromatic Bond Count12
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB05708 Stereoisomeric match
DescriptionGTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006. GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention related and memory related tasks (Kitagawa, et al. Neuropsychopharmacology (2003), 28, 542-551).
  • 3-(2,4-dimethoxybenzylidene)anabaseine
  • Dimethoxybenzylidene anabaseine
  • DMXB-A
  • DMXB-Anabaseine
Affected OrganismHumans and other mammals
IndicationInvestigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders.
Mechanism of actionAuditory sensory gating, a biological measurement of the ability to suppress the evoked response to the second of two auditory stimuli, is diminished in people with schizophrenia. Deficits in sensory gating are associated with attentional impairment, and may contribute to cognitive symptoms and perceptual disturbances. This inhibitory process, which involves the alpha(7) nicotinic receptor mediated release of gamma-aminobutyric acid (GABA) by hippocampal interneurons, represents a potential new target for therapeutic intervention in schizophrenia. GTS-21 is an orally active alpha-7 nicotinic acetylcholine (nACh) receptor agonist.
  • Benzene Derivatives
  • Chemical Actions and Uses
  • Cholinergic Agents
  • Cholinergic Agonists
  • Heterocyclic Compounds
CAS number148372-04-7

Drug Targets

NameSequence SearchPharmacological ActionActions
Neuronal acetylcholine receptor subunit alpha-7MRCSPGGVWLALAASLLHVSLQGEFQRKLYKELVKNYNPLERPVANDSQP...unknown
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682